Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) CTO David M. Spencer sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $7.04, for a total value of $70,400.00. Following the completion of the transaction, the chief technology officer now directly owns 89,939 shares of the company’s stock, valued at approximately $633,170.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of BLCM stock remained flat at $$6.25 on Friday. The stock had a trading volume of 539,479 shares, compared to its average volume of 334,293. The firm has a market capitalization of $270.93 million, a PE ratio of -2.20 and a beta of 0.54. The company has a current ratio of 10.24, a quick ratio of 10.24 and a debt-to-equity ratio of 0.32. Bellicum Pharmaceuticals Inc has a 12 month low of $5.02 and a 12 month high of $13.30.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.05). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.08 million. equities analysts forecast that Bellicum Pharmaceuticals Inc will post -2.37 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. increased its stake in shares of Bellicum Pharmaceuticals by 95.2% in the first quarter. Principal Financial Group Inc. now owns 160,100 shares of the biopharmaceutical company’s stock valued at $1,050,000 after buying an additional 78,070 shares during the period. Wasatch Advisors Inc. grew its stake in Bellicum Pharmaceuticals by 1,004.4% during the second quarter. Wasatch Advisors Inc. now owns 923,824 shares of the biopharmaceutical company’s stock worth $6,818,000 after purchasing an additional 840,175 shares during the period. Millennium Management LLC grew its stake in Bellicum Pharmaceuticals by 97.9% during the first quarter. Millennium Management LLC now owns 245,868 shares of the biopharmaceutical company’s stock worth $1,613,000 after purchasing an additional 121,608 shares during the period. Knott David M grew its stake in Bellicum Pharmaceuticals by 12.8% during the first quarter. Knott David M now owns 67,653 shares of the biopharmaceutical company’s stock worth $444,000 after purchasing an additional 7,669 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in Bellicum Pharmaceuticals by 52.8% during the first quarter. Commonwealth Equity Services LLC now owns 18,888 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 6,530 shares during the period. 59.31% of the stock is owned by institutional investors.

A number of equities analysts have issued reports on the company. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 10th. BidaskClub cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. Citigroup lowered their target price on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, August 9th. Finally, Cantor Fitzgerald set a $18.00 target price on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.48.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

See Also: New Google Finance Tool and Screening Stocks

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.